Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt

Background/aims In cirrhosis portal hypertension can promote bacterial translocation and increase serum endotoxin levels. Vice versa, endotoxin aggravates portal hypertension by induction of systemic and splanchnic vasodilation, and by triggering hepatic inflammatory response via tumor necrosis factor &agr; (TNF&agr;). However, the hepatic elimination of endotoxin in cirrhotic patients with severe portal hypertension, in the absence of acute complications, has not been investigated so far. Methods Twenty patients with alcoholic liver cirrhosis received transjugular intrahepatic portosystemic shunt at an event-free interval for either refractory ascites or recurrent bleeding. During the transjugular intrahepatic portosystemic shunt procedure portal and hepatic venous blood samples were obtained and endotoxin levels were measured by a chromogenic limulus-assay. In 16 of these patients an enzyme-linked immunosorbent assay was used to measure levels of the soluble TNF&agr;-receptors sTNF-R55 and sTNF-R75. Results Portal venous endotoxin levels correlated with portal vein velocity (P=0.03) and arterial systolic blood pressure (P=0.007). Portal endotoxin levels correlated with portal venous sTNF-R75-levels (P=0.039; r=0.521) and hepatic venous sTNF-R55-levels (P=0.009; r=0.669). Hepatic venous levels of both sTNF-R55 and sTNF-R75 correlated directly with the model for end-stage liver disease-score, and inversely with cholinesterase. However, we did not find significant differences in endotoxin levels nor in sTNF-R55-levels and sTNF-R75-levels between portal and hepatic venous blood. Conclusion Endotoxin levels correlated with hemodynamic derangement in cirrhotic severe portal hypertension, and with levels of soluble TNF&agr;-receptors. Soluble TNF&agr;-receptor levels correlated with the severity of liver dysfunction. However, in this study an endotoxin concentration gradient across the liver was absent, suggesting negligible primary hepatic endotoxin elimination in the absence of complications.

[1]  P. Hayes,et al.  Acute endotoxemia following transjugular intrahepatic stent-shunt insertion is associated with systemic and cerebral vasodilatation with increased whole body nitric oxide production in critically ill cirrhotic patients. , 2011, Journal of hepatology.

[2]  James P. Nolan,et al.  The role of intestinal endotoxin in liver injury: A long and evolving history , 2010, Hepatology.

[3]  Nolan Jp,et al.  The role of intestinal endotoxin in liver injury: A long and evolving history , 2010 .

[4]  R. Rao.  Endotoxemia and gut barrier dysfunction in alcoholic liver disease , 2009, Hepatology.

[5]  S. Raptis,et al.  Intestinal decontamination improves liver haemodynamics in patients with alcohol‐related decompensated cirrhosis , 2009, Alimentary pharmacology & therapeutics.

[6]  T. Sauerbruch,et al.  Mechanisms of extrahepatic vasodilation in portal hypertension , 2008, Gut.

[7]  D. Thabut,et al.  High‐density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats , 2007, Hepatology.

[8]  T. Sauerbruch,et al.  Circadian rhythm of fasting and postprandial portal blood flow in cirrhosis , 2006, Scandinavian journal of gastroenterology.

[9]  R. Moreau,et al.  Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling. , 2005, Gastroenterology.

[10]  R. Wiest,et al.  Bacterial translocation (BT) in cirrhosis , 2005, Hepatology.

[11]  R. Wiest,et al.  Gut microflora in the pathogenesis of the complications of cirrhosis. , 2004, Best practice & research. Clinical gastroenterology.

[12]  M. Álvarez-Mon,et al.  Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin. , 2004, Journal of hepatology.

[13]  R. Groszmann,et al.  Bacterial translocation up‐regulates GTP‐cyclohydrolase I in mesenteric vasculature of cirrhotic rats , 2003, Hepatology.

[14]  G. Jennings,et al.  The Effect of Selective Intestinal Decontamination on the Hyperdynamic Circulatory State in Cirrhosis , 2003, Annals of Internal Medicine.

[15]  C. Margarit,et al.  Increased tumour necrosis factor α production in mesenteric lymph nodes of cirrhotic patients with ascites , 2003, Gut.

[16]  R. Wiest,et al.  Bacterial translocation in the gut , 2003 .

[17]  M. Navasa,et al.  Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis , 2002, Hepatology.

[18]  P. Raab,et al.  Hemodynamic Effects of Propranolol and Nitrates in Cirrhotics with Transjugular Intrahepatic Portosystemic Stent-Shunt , 2002, Scandinavian journal of gastroenterology.

[19]  H. Sørensen,et al.  Population-based study of the risk and short-term prognosis for bacteremia in patients with liver cirrhosis. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  H. Schild,et al.  Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study , 2000, Gut.

[21]  R. Groszmann,et al.  Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. , 1999, The Journal of clinical investigation.

[22]  A. Flahault,et al.  Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. , 1998, Journal of hepatology.

[23]  C. Sabin,et al.  Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage , 1998, Hepatology.

[24]  S. D. Lee,et al.  Hyperdynamic circulation of cirrhotic rats with ascites: role of endotoxin, tumour necrosis factor-alpha and nitric oxide. , 1997, Clinical science.

[25]  D. Valla,et al.  Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. , 1995, Gastroenterology.

[26]  S. D. Lee,et al.  Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. , 1995, Journal of hepatology.

[27]  G. Tilz,et al.  Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis , 1995, European journal of haematology.

[28]  J. Llovet,et al.  Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis , 1994, Hepatology.

[29]  D. Fuchs,et al.  Tumor necrosis factor alpha and soluble tumor necrosis factor receptors in individuals with human immunodeficiency virus infection. , 1994, Immunology letters.

[30]  N. Liabakk,et al.  Serum Levels of Tumor Necrosis Factor-α (TNFα) and Soluble TNF Receptors in Human Immunodeficiency Virus Type 1 Infection-Correlations to Clinical, Immunologic, and Virologic Parameters , 1994 .

[31]  T. Ueno,et al.  Bacterial infection in cirrhosis, with and without hepatocellular carcinoma. , 1993, The American journal of gastroenterology.

[32]  O. Bulbena,et al.  Increased serum nitrite and nitrate levels in patients with cirrhosis: Relationship to endotoxemia , 1993, Hepatology.

[33]  R. Ulevitch,et al.  Lipopolysaccharide binding protein enhances the responsiveness of alveolar macrophages to bacterial lipopolysaccharide. Implications for cytokine production in normal and injured lungs. , 1992, The Journal of clinical investigation.

[34]  X. Cussó,et al.  Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. , 1992, Gastroenterology.

[35]  S. Moncada,et al.  Hyperdynamic circulation in cirrhosis: a role for nitric oxide? , 1991, The Lancet.

[36]  H. Holtmann,et al.  Soluble forms of tumor necrosis factor receptors (TNF‐Rs). The cDNA for the type I TNF‐R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. , 1990, The EMBO journal.

[37]  J. Llach,et al.  Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double‐blind, placebo‐controlled trial , 1990, Hepatology.

[38]  E. Dupont,et al.  Excessive in vitro bacterial lipopolysaccharide‐induced production of monokines in cirrhosis , 1990, Hepatology.

[39]  M. Kutner,et al.  Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis , 1988, Hepatology.

[40]  V. Arroyo,et al.  Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage , 1985, Hepatology.

[41]  Kirby R Gross,et al.  Impaired Bacterial Clearance and Trapping in Obstructive Jaundice , 1984, Annals of surgery.

[42]  C. Galanos,et al.  Time course of cellular distribution of endotoxin in liver, lungs and kidneys of rats. , 1982, British journal of experimental pathology.

[43]  R. Ulevitch,et al.  The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. , 1979, Journal of immunology.

[44]  J. Nolan,et al.  KUPFFER CELLS AND CIRRHOSIS , 1975, The Lancet.

[45]  M. Abrahamson.  Pulmonocardiac failure associated with deformity of the chest. , 1959, Lancet.

[46]  A. Braude,et al.  Studies with Radioactive Endotoxin. II. Correlation of Physiologic Effects with Distribution of Radioactivity in Rabbits Injected with Lethal Doses of E. Coli Endotoxin Labelled with Radioactive Sodium Chromate , 1955 .

[47]  R. Wiest,et al.  Gastrointestinal disorders of the critically ill. Bacterial translocation in the gut. , 2003, Best practice & research. Clinical gastroenterology.

[48]  G. Adler,et al.  Gastrointestinal disorders of the critically ill. Shock and acute pancreatitis. , 2003, Best practice & research. Clinical gastroenterology.

[49]  G. Garcia‐Tsao.  Bacterial translocation: cause or consequence of decompensation in cirrhosis? , 2001, Journal of hepatology.

[50]  K. Kaneda,et al.  Liver microvascular architecture: an insight into the pathophysiology of portal hypertension. , 1999, Seminars in liver disease.

[51]  J. Villeneuve,et al.  Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis , 1999, American Journal of Gastroenterology.

[52]  N. Liabakk,et al.  Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters. , 1994, The Journal of infectious diseases.

[53]  E. Strauss,et al.  A prospective study of bacterial infections in patients with cirrhosis. , 1993, Journal of hepatology.

[54]  H. Prytz,et al.  Letter: Kupffer cells and cirrhosis. , 1975, Lancet.

[55]  A. Braude,et al.  Studies with radioactive endotoxin. II. Correlation of physiologic effects with distribution of radioactivity in rabbits injected with radioactive sodium chromate. , 1955, The Journal of clinical investigation.